According to the hygiene hypothesis, triggering the immune system with microbial components during childhood balances the inherent Th2 bias. In contrast, specific immunotherapy involves exposure of the patient to the allergen in order to achieve desensitization to subsequent contact. From these data we conclude that BPPcysMPEG was able to influence the immune system with regard to subsequent allergen contact by TLR2/6 agonization.
Introduction
Allergic immune responses to harmless antigens are characterized by an imbalance between T regulatory, T helper 1 (Th1), and T helper 2 (Th2) cells. In addition, Th17 cells have recently been described to contribute to the pathogenesis of allergic asthma (Zhao et al., 2009 ). The development of allergic airway diseases includes an initial sensitization phase to an aeroallergen. During this sensitization phase, priming of allergen-specific CD4-positive Th2 lymphocytes results in secretion of Th2-associated cytokines, which induce immunoglobulin class switching and thus IgE production of B cells, mucus secretion, and activation of endothelial cells. This facilitates migration of Th2 cells and eosinophils into the tissue. The binding of IgE to the high-affinity receptor of IgE (FcεRI) sensitizes mast cells and basophils for subsequent cross-linking by the allergen. This cross-linking of the IgE-FcεRI-complex leads to degranulation of preformed mediators including histamine, prostaglandines, leukotrienes, as well as cytokines and chemokines characterizing the immediate phase of an allergic immune response (Akdis, 2006; Romagnani, 2004) . During the late phase of an allergic reaction, persistence of an allergic airway inflammation depends on the presence of CD4-positive T lymphocytes (Brusselle et al., 1994; Cohn et al., 1998; Gavett et al., 1994) . In the milieu of a polarizing Th2 cytokine pattern, T lymphocytes differentiate into Th2 cells in the peripheral lymphoid organs upon antigen recognition. They are characterized by a distinct cytokine pattern and associated effector functions, including induction of hyper-IgE, eosinophil survival, mucus hyperproduction, and interaction with resident tissue cells (Abbas et al., 1996; Akdis et al., 2004; O'Garra, 1998) .
Although the underlying mechanisms of allergic diseases are not fully understood, their increasing prevalence seems to be associated with environmental factors. The hygiene hypothesis postulates that the decreased incidence of infectious diseases and the urbanized lifestyle during childhood are related to an increased incidence of immunological diseases (Bach, 2002) . During infection, highly conserved microbial structures, the pathogen-associated molecular patterns (PAMP), are recognized by pattern-recognition receptors (PRR) expressed on a variety of cells of the innate immune system. Signaling through PRR induces proinflammatory cytokine release, thereby providing a constant Th1 triggering of the immune system. Based on this, several approaches for the treatment of allergic diseases focus on targeting the innate immune system to induce a counterbalancing inflammatory immune response (Akdis et al., 2007; Lombardi et al., 2008; Sel et al., 2007) . Toll-like receptors (TLR) are part of the PRR-mediated innate immunity and are widely expressed on a variety of cell types, including immune cells as well as non hematopoietic epithelial and endothelial cells (West et al., 2006) . Ten TLR in humans and 13 in mice have been identified so far (Beutler, 2004) .
TLR2 recognizes a wide range of microbial products and generally functions as a heterodimer with either TLR1 or TLR6 (Ozinsky et al., 2000) . Recent studies showed that triacylated lipoproteins are preferentially sensed by the TLR2/1 heterodimer, whereas diacylated lipoproteins are sensed by the TLR2/6 heterodimer (Takeuchi et al., 2002) . Genetic variations in TLR2 have been found to affect susceptibility to allergies and asthma (Eder et al., 2004) , whereas TLR4 did not (Raby et al., 2002) . In addition, a recent study demonstrated that a TLR2 agonist in German cockroach frass mediates protection in allergic airway inflammation in mice (Page et al., 2009) . The pharmaceutical efficacy of the Mycoplasma fermentans-derived macrophage-activating lipopeptide of 2 kDa (MALP-2), which signals through TLR2 and TLR6 (Takeuchi et al., 2001) , was shown in several approaches concerning wound-healing (Niebuhr et al., 2008) , vaccination (Borsutzky et al., 2006) , tumor therapy (Schneider et al., 2004) , infection (Reppe et al., 2009) , and treatment of airway inflammation (Weigt et al., 2005) . The synthetic MALP-2 derivate pegylated bisacyloxypropylcysteine (BPPcysMPEG) shows improved properties regarding solubility. A recent study by our group demonstrated the therapeutic potential of BPPcysMPEG in combination with IFN-γ to reduce allergic airway inflammation in chronic respiratory sensitization to Timothy grass pollen antigens (Fuchs et al., 2009) . In the present study, we aimed to evaluate the efficacy of BPPcysMPEG alone to modulate antigen presenting cells and the subsequent immune response in a human in vitro allergy model. Based on these findings, the potential of preventive administration of BPPcysMPEG to reduce allergic airway inflammation by TLR2/6 agonization in a mouse model was investigated.
Material and methods

Patients
The study included male and female subjects (aged 18-55 years) with a history of allergy to grass pollen and a positive skin prick test for Phleum pratense pollen (ALK Scherax, Hamburg, Germany) at or within 12 months prior to their first visit. During a first visit, demographic data including medical and allergy (atopic) history, concomitant medication review, physical examination, vital signs, laboratory tests (hematology, biochemistry, and urinalysis), skin prick test (if not performed within the last 12 month), and a pregnancy test for female subjects were obtained. During a second visit, 200 ml of blood were drawn. The study was approved by the ethics committee of the Hannover Medical School (Hannover, Germany) and was performed according to standard operating procedures.
Human in vitro allergy model
Generation of immature dendritic cells (iDC) and co-culture of stimulated dendritic cells (DC) were performed as recently described (Weigt et al., 2004) . In brief, iDC were generated from CD14-positive monocytes obtained from whole blood of allergic donors. On day 5, cells were stimulated with 20 µg/ml P. pratense extract (kindly provided by ALK Abello, Hørsholm, Denmark) with or without 25 ng/ml BPPcysMPEG (patent number WO 2004/009125 A2 Mühlradt/Morr) for two additional days. On day 7, cells were harvested and co-cultured with autologous lymphocytes for five days (Fig. 1 A) .
Animal model
Female BALB/c mice (Charles River, Sulzfeld, Germany) aged 6-8 weeks were sensitized intraperitoneally (i.p.) on days 0, 14, and 21 with 5 µg recombinant P. pratense major allergen 5 (rPhl p5) (Biomay, Vienna, Austria) or saline adsorbed to 1 mg aluminium hydroxide (alum) (Pierce, Rockford, USA) in a total volume of 200 µl sterile saline. From day 28 to day 35, animals were treated daily with 1 µg BPPcysMPEG with or without the allergen, administered intranasally (i.n.). Controls received allergen or saline. I.n. challenges with P. pratense extract containing 9 µg of the major allergen Phl p5 in 50 µl sterile saline were performed on days 42 and 43. On day 44, animals were sacrificed (Fig. 1 B) . The different study groups are depicted in Table 1 . Animal experiments were performed in compliance with the German animal protection law under a protocol approved by the competent governmental authority.
Animal dissection
Animals were sacrificed by i.p. injection of an overdose of pentobarbital-Na (Merial, Hallbergmoos, Germany). Bronchoalveolar lavage (BAL) was performed twice with 0.8 ml ice-cold saline. The fluid was then centrifuged and aliquots of supernatant were stored at -80 °C until analysis of proteins. The cell pell et was resuspended in 0.5 ml PBS and a differential cell count was performed. Mediastinal lymph nodes and the spleen were removed and properties were determined.
Allergen-specific restimulation of cells from mediastinal lymph nodes and splenocytes
Using 96-well round bottom plates, 1 x 10 5 cells from mediastinal lymph nodes or splenocytes were cultured in RPMI 1640 (Lonza, Verviers, Belgium) containing 5% FCS (Sigma, Taufkirchen, Germany) with or without 20 µg/ml P. pratense extract in a total volume of 200 µl under normal cell culture conditions. Cells stimulated with concanavalin A (ConA) served as positive control.
Culture supernatants were taken after five days and aliquots were stored at -20 °C until analysis of cytokines.
Differential cell count of lung cells
One x 10 5 cells were spun onto glass slides using a cytocentrifuge, air-dried, and stained according to Pappenheim. Three hundred cells per slide were counted and differentiated by light microscopy according to standard morphologic criteria. Cell numbers were determined for macrophages, eosinophils, neutrophils, and lymphocytes.
Flow cytometric analysis
One x 10 5 DC were washed with phosphate buffered saline (PBS), blocked with goat serum/PBS and stained with FITC-labeled murine-anti-human CD14 in combination with either PE-labeled murine-anti-human CD40, CD80, CD86, CD83, or HLA-DR, or with the corresponding isotype controls (all BD Biosciences, Heidelberg, Germany) for 30 min at 4°C. Cells were washed and analyzed using the Cytomics FC 500 Flow Cytometry System (Beckman Coulter, Krefeld, Germany).
Determination of proliferation
Human cells were pulsed with 5 µCi/ml added and the plates were sealed. Counts per minute were determined on a Topcount
Microplate Scintillation Counter (Canberra-Packard, Dreieich, Germany).
Determination of cytokines
Cytokines in cell culture supernatants of stimulated DC were determined with enzyme linked immunosorbent assay (ELISA) technique using DuoSet® ELISA Development Systems (R&D Systems, Wiesbaden, Germany) according to the manufacturer´s instructions. Cytokines in cell culture supernatants of the allergy model in vitro were determined with electrochemiluminescence detection technology using a human Th1/Th2 (10-Plex) Ultra-Sensitive Kit (Meso Scale Discovery, Gaithersburg, USA) according to the manufacturer´s instructions. The detection limit of this assay was 0.6 pg/ml. Similarly, cytokines in cell culture supernatants and BAL fluid of the mouse model of allergic airway inflammation were determined using a mouse Th1/Th2 (9-Plex) Ultra-Sensitive Kit (Meso Scale Discovery, Gaithersburg, USA)
according to the manufacturer´s instructions. The detection limit of this assay was 2.4 pg/ml.
Statistical analysis
Values obtained from the in vitro as well as from the in vivo model are given either as mean ± standard error of the mean (SEM) of a minimum of four independent experiments or as a pool sample from five individual experiments. Statistical analysis was performed using the software Probability values of *p < 0.05, **p < 0.01, and ***p < 0.001 were considered significant. To identify tendencies, results were analyzed with the unpaired t-test. Probability values of p < 0.1 indicated a trend.
Results
Immunomodulatory potential of BPPcysMPEG in a human in vitro allergy model
In a human in vitro allergy model the potential of BPPcysMPEG to mediate immunomodulation was evaluated. First, the effects of the TLR2/6 agonist on maturation of DC were determined.
Second, its modulatory potential on co-cultures of DC with autologous lymphocytes was analyzed. The maturation of iDC was characterized by an altered pattern of co-stimulatory molecules on their cell surface and by secretion of proinflammatory cytokines. BPPcysMPEG enhanced expression of CD40, CD80, CD83, and HLA-DR as compared to medium control (Fig.   2 A) . In addition, the presence of BPPcysMPEG stimulated secretion of the proinflammatory cytokine TNF-α by DC either alone as compared to medium control, or in combination with the allergen as compared to the allergen control (Fig. 2 B) . Neither IL-10 nor IL-12 was induced (data not shown). Furthermore, stimulated cells were co-cultured with autologous lymphocytes and analyzed for proliferation and cytokine secretion to determine whether BPPcysMPEG modulates the outcome of an immune response. Fig. 3 A shows that P. pratense extract-induced allergen-specific proliferation was enhanced when BPPcysMPEG was co-administered with the allergen. However, BPPcysMPEG did not induce proliferation on its own (Fig. 3 A) . In accordance with the proliferation data, co-administration of BPPcysMPEG enhanced the allergen-induced secretion of the Th2-associated cytokine IL-5 (Fig. 3 B) as well as the Th1-associated cytokine IFN-γ (Fig. 3 C) and the proinflammatory cytokine TNF-α (Fig. 3 D) as compared to the allergen control.
Thus, the human in vitro allergy model using monocyte-derived DC and autologous lymphocytes clearly displayed the potential of BPPcysMPEG to induce maturation of DC, as well as to enhance a specific immune response to a co-administered allergen via TLR2/6 agonization.
Local treatment with BPPcysMPEG reduced allergic airway inflammation in mice
The immunomodulatory properties exhibited by BPPcysMPEG in the in vitro studies provided the rationale to evaluate its potential to reduce parameters of allergic airway inflammation in vivo. To this end, preventive immunotherapy with BPPcysMPEG was performed in sensitized mice.
Administration of BPPcysMPEG alone did not alter total cellular influx as compared to the positive control (data not shown). Cell differentiation showed increased numbers of alveolar macrophages (Fig. 4 A) , whereas the number of eosinophils tended to be decreased as compared to the positive control (Fig. 4 B) . The levels of neutrophils (Fig. 4 C) and lymphocytes (Fig. 4 D) were not altered by the treatment with BPPcysMPEG alone as compared to the positive control. Similarly, co-administration of allergen and BPPcysMPEG did not alter total cellular influx as compared to the allergen control (data not shown). While the influx of alveolar macrophages (Fig. 4 A) was enhanced, the influx of eosinophils (Fig. 4 B) and lymphocytes (Fig.   4 D) was reduced as compared to the allergen control. Levels of neutrophils were not altered as compared to the allergen control (Fig 4 C) .
For evaluation of the cytokine balance, the production of both Th1 and Th2 cytokines in BAL fluid was measured using electrochemiluminescence detection technology. The treatment with BPPcysMPEG tended to reduce levels of IL-2 (Fig. 5 A) as well as diminished those of the Th2 cytokines IL-4 (Fig. 5 B) and IL-5 (Fig. 5 C) as compared to the positive control. In contrast, IL-12 levels (Fig. 5 D) tended to be elevated as compared to the positive control, thereby indicating a shift towards a Th1 immune response. The level of IFN-γ, however, was below the detection limit (data not shown). Co-administration of allergen and BPPcysMPEG reduced both IL-2 (Fig. 5 A) and IL-12 levels (Fig. 5 D) as compared to the allergen control. In contrast, IL-4 (Fig. 5 B) and IL-5 levels ( Fig. 5 C) were not altered as compared to the allergen control.
The question of whether the in vivo treatment with BPPcysMPEG affected the local or the systemic immune response was then further addressed by determining the properties of cells from mediastinal lymph nodes and splenocytes. Upon allergen-specific restimulation, treatment with BPPcysMPEG induced a Th1-dominated cytokine milieu in mediastinal lymph nodes as compared to the positive control (Fig. 6 A) , when calculating the alteration of IL-4 and IFN-γ levels. In contrast, allergen-specific cytokine secretion in splenocytes was reduced as compared to the positive control (Fig. 6 B) . Co-administration of allergen and BPPcysMPEG diminished the secretion of both IL-4 and IFN-γ upon allergen-specific restimulation in cells from mediastinal lymph nodes (Fig. 6 A) and splenocytes ( Fig. 6 B) , respectively as compared to the allergen control.
Discussion
Modulation of T cell responses in allergic diseases can be achieved in several ways, including the triggering of the innate immune system with microbial components and allergen-specific immunotherapy (Ebner et al., 1997; Secrist et al., 1993) . Recent studies also showed that amelioration of allergic airway disease can be achieved by using components which induce Th1 cell responses rather than regulatory responses (Drachenberg et al., 2001; Patel et al., 2005) . The potential of MALP-2 co-administered with IFN-γ to induce a shift towards a Th1 counterbalancing immune response was shown both in vitro (Weigt et al., 2004) and in vivo (Weigt et al., 2005) . In addition, according to the results obtained with the precursor molecule, BPPcysMPEG in combination with IFN-γ had the potential to reduce parameters of allergic airway inflammation (Fuchs et al., 2009) . In these studies, however, the efficacy of the TLR2/6 agonist was shown to depend on the presence of IFN-γ. As In the present study, the effects of allergen-specific immunotherapy either in the presence or absence of BPPcysMPEG were controversial. Although the enhanced influx of eosinophils and lymphocytes after allergen treatment indicated an amplification of allergic airway inflammation, this effect was not accompanied by enhanced levels of Th2 cytokines. In addition, the IL-12 level was enhanced, suggesting a shift towards Th1. In the presence of BPPcysMPEG the measured parameters were diminished as compared to allergen-treated mice, but were still enhanced as compared to positive control. The failure of allergen-specific immunotherapy might be due to the animal model, as many studies concerning allergen-specific immunotherapy were performed in long-term models (Kildsgaard et al., 2007) . Furthermore, the allergen dose as well as time and 
